Keywords: Migraine drugs, Market forecasts, Triptans, MAP Pharma, Alleran, Botox, Levadex, CoLucid, Lasmiditan, Decision Resources

Migraine drug sales to grow to $5.8 billion in 2021 in major markets

Article | 18 November 2012

Print This

Despite a decline in sales owing to the generic entry of most triptans, the launch of emerging acute treatments and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in